PharmAthene, Inc.
One Park Place
Suite 450
Annapolis,
MD 21401
United States - Map
Phone: 410-269-2600
Fax: 410-269-2601
Web Site: http://www.pharmathene.com
| PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Its product candidates include SparVax, a recombinant protective antigen (rPA) anthrax vaccine for use against human anthrax infection has completed one Phase I and two Phase II clinical trials; and Valortim, a human monoclonal antibody that has completed Phase I clinical trial is used for the prevention and treatment of anthrax infection. The companys product candidates also include Protexia, a nerve agent countermeasure is a recombinant form of human butyrylcholinesterase, and a naturally occurring enzyme in the Phase I clinical trial, which mimics a natural bioscavenger for the treatment or prevention of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. In addition, its product candidates include RypVax, a recombinant dual antigen vaccine that is used to protect individuals before exposure to Yersinia pestis (a pneumonic and bubonic plague); and rPA anthrax vaccine, which is stored, transported, and used without the need for a conventional cold chain for civilian biodefense deployment within the SNS. The companys customers include National Institute of Allergy and Infectious Diseases, the U.S. Department of Defense, Biomedical Advanced Research and Development Authority, and the U.S. National Institutes of Health. It has a collaboration agreement with Medarex, Inc. to develop and commercialize MDX-1303 (Valortim). PharmAthene, Inc. was founded in 2001 and is headquartered in Annapolis, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. David P. Wright , 61
Chief Exec. Officer, Pres, Exec. Director and Member of Gov. Affairs Committee |
$
445.00K | N/A | Mr. Eric I. Richman , 47
Sr. VP of Bus. Devel. and Strategic Planning |
$
306.00K | N/A | Mr. Christopher C. Camut , 46
VP of Gov. Contracting and Special Projects |
$
272.00K | N/A | Mr. Kevin Price ,
Pres |
N/A
| N/A | Mr. Charles A. Reinhart III,
Chief Financial Officer and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
Profile
